TABLE 2.
Antibody binding to BBK32(51–80) component peptides
| Serum type | Binding result (no. of samples/total no. of samples [%]) for: |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBK32(51–65) |
BBK32(56–70) |
BBK32(61–75) |
BBK32(66–80) |
|||||||||
| Positive | Equivocal | Negative | Positive | Equivocal | Negative | Positive | Equivocal | Negative | Positive | Equivocal | Negative | |
| Early Lyme (EM+) | 25/109 (22.9)a | 9/109 (8.3) | 75/109 (68.8) | 17/109 (15.6)b | 13/109 (11.9) | 79/109 (72.5) | 19/109 (17.4)b | 12/109 (11.0) | 78/109 (71.6) | 18/109 (16.5)b | 8/109 (7.3) | 83/109 (76.2) |
| Lyme arthritis | 5/19 (26.3) | 5/19 (26.3) | 9/19 (47.4) | 1/19 (5.3) | 1/19 (5.3) | 17/19 (89.5) | 2/19 (10.6) | 6/19 (31.6) | 11/19 (57.9) | 3/19 (15.8) | 6/19 (31.6) | 10/19 (52.6) |
| Nonendemic healthy | 1/100 (1.0)a | 4/100 (4.0) | 95/100 (95.0) | 2/100 (2.0)b | 3/100 (3.0) | 96/100 (95) | 2/100 (2.0)b | 3/100 (3.0) | 96/100 (95) | 1/100 (1.0)b | 4/100 (4.0) | 95/100 (95.0) |
| Endemic healthy | 1/35 (2.9)a | 0/35 (0.0) | 34/35 (97.1) | 0/35 (0.0)b | 1/35 (2.9) | 34/35 (97.1) | 1/35 (2.9)b | 1/35 (2.9) | 33/35 (94.3) | 2/35 (5.7) | 2/35 (5.7) | 31/35 (88.6) |
| RA | 1/37 (2.7)a | 0/37 (0.0) | 36/37 (97.3) | 1/37 (2.7)b | 1/37 (2.7) | 35/37 (94.6) | 0/37 (0.0)b | 3/37 (5.4) | 35/37 (94.6) | 0/37 (0.0)b | 1/37 (2.7) | 36/37 (97.3) |
| Syphilis | 2/25 (8.0) | 4/25 (16.0) | 19/25 (76.0) | 0/25 (0.0)b | 1/25 (4.0) | 24/25 (96.0) | 1/25 (4.0)b | 0/25 (0.0) | 24/25 (96.0) | 2/25 (8.0) | 2/25 (8.0) | 21/25 (84) |
a
P < 0.005, comparing antibody binding in early Lyme disease patient sera to antibody binding the indicated control patient sera.
b
P < 0.05, comparing antibody binding in early Lyme disease patient sera to antibody binding the indicated control patient sera.